Targeting pml-rarα with retinoids

Eytan M. Stein, Martin S. Tallman*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

All-trans retinoic acid (ATRA), an oral retinoic acid derivative, revolutionized the treatment and prognosis of acute promyelocytic leukemia (APL) and anticipated the current age of targeted cancer therapy. The past 25 years have seen an international effort to design multicenter clinical trials that identify the optimal use of ATRA in patients with APL. Indeed, since ATRA is so effective, contemporary clinical trials aim to de-escalate conventional cytotoxic chemotherapy, as has been the case with other highly curable malignancies such as childhood acute lymphoblastic leukemia and Hodgkin’s lymphoma. In this chapter, we review and reflect upon the seminal clinical trials that have led to the current adoption of ATRA as the standard of care for treating APL.

Original languageEnglish (US)
Title of host publicationTargeted Therapy of Acute Myeloid Leukemi
PublisherSpringer New York
Pages489-507
Number of pages19
ISBN (Electronic)9781493913930
ISBN (Print)9781493913923
DOIs
StatePublished - Jan 1 2015

Keywords

  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • Consolidation
  • Induction
  • Maintenance

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint

Dive into the research topics of 'Targeting pml-rarα with retinoids'. Together they form a unique fingerprint.

Cite this